Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland

NCT06889948 is registered in ClinicalTrials.gov with Helsinki University Central Hospital as lead sponsor.

NCT NCT06889948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06889948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland
Lead sponsor
Helsinki University Central Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 19, 2024
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, kidney failure, paraproteinemias